Gain Therapeutics (GANX) Market Capitalization (2021 - 2026)

Gain Therapeutics has reported Market Capitalization for 6 years, with the latest figure at $88.0 million in Q2 2026.

• On a quarterly basis, Market Capitalization rose 58.84% year-over-year to $88.0 million in Q2 2026; TTM through Jun 2026 was $88.0 million, a 58.84% increase from a year earlier, with the FY2025 full-year figure at $106.2 million, up 81.14% from the prior year.
• Market Capitalization was $88.0 million for Q2 2026 at Gain Therapeutics, up from $82.4 million in the prior quarter.
• The five-year high for Market Capitalization was $106.2 million in Q4 2025, with the low at $24.6 million in Q2 2024.
• Average Market Capitalization over 5 years is $56.4 million, with a median of $55.1 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2025: Market Capitalization plunged 69.44% in 2022, then surged 125.19% in 2025.
• Over 5 years, Market Capitalization stood at $37.2 million in 2022, then rose by 14.21% to $42.5 million in 2023, then soared by 37.96% to $58.6 million in 2024, then surged by 81.14% to $106.2 million in 2025, then slipped by 17.12% to $88.0 million in 2026.
• The last three Market Capitalization figures came in at $88.0 million (Q2 2026), $82.4 million (Q1 2026), and $106.2 million (Q4 2025), per Business Quant data.